Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 817 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastroesophageal Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure

NCT01093339
View directory record Official record
Conditions
Gastroesophageal Disease
Interventions
Not listed
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Jul 24, 2026, 4:08 AM EDT
Withdrawn Phase 4 Interventional

Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs

NCT02988063
View directory record Official record
Conditions
Leg Ulcer, Veins, Varicose, Venous Ulcer, Reflux, Venous Reflux, Venous Leg Ulcer, Varicose Veins, Varicose Ulcer, Varicose Veins Leg
Interventions
Polidocanol Endovenous Microfoam (PEM)
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
PRT7732
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

NCT04491734
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
maltosyl-isomalto-oligosaccharides (MIMO)
Dietary Supplement
Lead sponsor
ISOThrive Inc.
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Rapid Assessment of Esophageal Adenocarcinoma Risk Test

NCT03366012
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Cytosponge
Device
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00069953
View directory record Official record
Conditions
Esophageal Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
97
States / cities
Burbank, California • Hayward, California • Mission Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers

NCT00584675
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dx-pH Measurement Probe
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Jul 24, 2026, 4:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction

NCT01401699
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Optical Frequency Domain Imaging (OFDI)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 24, 2026, 4:08 AM EDT
Withdrawn Not applicable Interventional

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NCT05409378
View directory record Official record
Conditions
Aortic Regurgitation
Interventions
The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
Device
Lead sponsor
HLT Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 24, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT01142388
View directory record Official record
Conditions
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Cancer AJCC v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
232
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Effect of Acid Suppression Medication on Pediatric Microbiome

NCT02016820
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Omeprazole (suspension), Lifestyle Modification
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
0 Years to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 24, 2026, 4:08 AM EDT
Completed No phase listed Observational

Laparoscopic Revision of Vertical Banded Gastroplasty to Gastric Bypass

NCT01041131
View directory record Official record
Conditions
Clinically Severe Obesity, Inadequate Weight Loss, Obesity Recidivism
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Jul 24, 2026, 4:08 AM EDT
Active, not recruiting No phase listed Observational

Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease

NCT00260572
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Questionnaires to evaluate QOL, Questionnaires to evaluate heartburn and quality of life, Questionnaire to evaluate satisfaction with treatment, Questionnaire to evaluate presence or absence of pain
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

NCT06109467
View directory record Official record
Conditions
GastroEsophageal Cancer, Gastric Cancer
Interventions
Neratinib, Trastuzumab, Oxaliplatin, 5-Fluorouracil + leucovorin, Pembrolizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

NCT00470184
View directory record Official record
Conditions
Esophageal Cancer
Interventions
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

NCT04208958
View directory record Official record
Conditions
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions
VE800, Nivolumab, Vancomycin Oral Capsule
Biological · Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2Phase 3 Interventional

Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment

NCT00204698
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Aciphex
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell

NCT03130543
View directory record Official record
Conditions
Apparent Life Threatening Event, Gastroesophageal Reflux, Aspiration
Interventions
Rice cereal, Enfamil AR
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 1 Year
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jul 24, 2026, 4:08 AM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251758
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
99
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated May 17, 2010 · Synced Jul 24, 2026, 4:08 AM EDT
Not yet recruiting Not applicable Interventional

Antireflux Surgery Without Preoperative Esophageal Manometry

NCT07659080
View directory record Official record
Conditions
GERD, Hiatal Hernia, Heartburn, Paraesophageal Hernia, Gastroesophageal Reflux
Interventions
Preoperative workup without high-resolution esophageal manometry, Standard preoperative workup with high-resolution esophageal manometry
Procedure
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

NCT01928290
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
Irinotecan, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

NCT00917462
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Junction Cancer
Interventions
Sorafenib, administered orally, CT/MRI
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jul 24, 2026, 4:08 AM EDT